Simulations Plus (SLP) Stock
Drug development simulation software for pharmaceutical companies. Here's the price, business snapshot, and what's worth knowing about Simulations Plus in October 2026.
Simulations Plus, Inc. (SLP) develops modelling and simulation software used across pharmaceutical and biotechnology R&D to predict absorption, distribution, metabolism, excretion and toxicity (ADMET) and support pharmacokinetic/pharmacodynamic (PK/PD) studies. Its products and consulting services aim to shorten drug development timelines and reduce experimental costs, with revenue from software licences, cloud offerings and professional services. As a smaller capitalisation company, growth often depends on adoption by drug developers, recurring licence renewals and occasional acquisitions. Investors should watch product validation, regulatory acceptance of in-silico methods and partnerships with larger CROs or pharma firms. Key risks include competitive pressure from larger vendors, reliance on R&D budgets and periodic revenue volatility. This is general educational information and not personal financial advice; suitability depends on your circumstances and risk tolerance, and past performance is no guarantee of future returns.
Simulations Plus (SLP) Stock Forecast
Analyst price target, next 12 months
$37.75
+104.1% vs today's $18.50
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Simulations Plus have a consensus 12-month target of $37.75, above the current price of $18.50.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Simulations Plus stock with a target price of $37.75, indicating potential growth.
Financial Health
Simulations Plus is performing well with solid revenue and cash flow, indicating strong business health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Recurring Revenue Potential
Licence and cloud subscriptions can create predictable income streams, though revenue can still vary with contract timing and renewals.
Tech Adoption Trend
In‑silico modelling is gaining regulatory and industry interest, which may support long‑term demand, but acceptance is gradual and not guaranteed.
Partnership Opportunities
Collaborations with pharmaceutical companies and CROs can expand reach; investors should note dependency risks and the competitive landscape.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
